Hopes Rise For Approval Of Melanoma Drug Ipilimumab, With Positive Front-line Results
This article was originally published in The Pink Sheet Daily
Executive Summary
As Bristol-Myers' ipilimumab nears its March 26 PDUFA date for second-line melanoma, drug demonstrates good results in front-line study. Will the data sway regulators?
You may also be interested in...
Protecting The Blind: FDA, BMS Took Pains To Ensure Integrity Of Ongoing Yervoy Study
FDA and Bristol-Myers Squibb went to great lengths to ensure that interim overall survival data from a first-line study of Yervoy (ipilimumab) could be reviewed by the agency in a manner that maintained the trial’s blind.
Protecting The Blind: FDA, BMS Took Pains To Ensure Integrity Of Ongoing Yervoy Study
FDA and Bristol-Myers Squibb went to great lengths to ensure that interim overall survival data from a first-line study of Yervoy (ipilimumab) could be reviewed by the agency in a manner that maintained the trial’s blind.
Yervoy Approval Has Shifted Development Landscape For Melanoma
With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.